| Project/Area Number |
26860872
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | サイトカイン / TGF-β / CTGF / IL-17A / 全身性強皮症 |
|---|
| Outline of Final Research Achievements |
Systemic sclerosis (SSc) is a fibrotic disorder, the etiology of which has not yet been fully elucidated. Recently, growing evidence has demonstrated that Th17cells and IL-17A plays a crucial role in the pathogenesis of SSc. The aim of this study was to examine the role of IL-17A in the progression of skin fibrosis in experimental murine fibrosis model by exogenous injection of growth factors. The loss of IL-17A significantly attenuated the rapid subcutaneous fibrosis and infiltration of inflammatory cells, to compared with wild-type. The daily injections of IL-17A alone induced fibrosis with time, and increased expression levels of TGF-β1 and CTGF mRNA. This findings suggest that IL-17A contributes to production of CTGF, thereby leading to persistent fibrosis.
In addition, with the aim of drug development, we attempt to administer IL-17A-inhibitor agent: ursolic acid. we improve such as the ideal concentration and method of administration.
|
